Acquisitions of Ownership Interests in Partner Companies and Funds - Additional Information (Detail) (USD $)
|
1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 33 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 2 Months Ended | 12 Months Ended | 8 Months Ended | 12 Months Ended | 1 Months Ended | 37 Months Ended | 1 Months Ended | 12 Months Ended | 6 Months Ended | 7 Months Ended | 1 Months Ended | 4 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Sep. 30, 2012
ThingWorx, Inc.
|
Feb. 28, 2011
ThingWorx, Inc.
|
Apr. 30, 2011
PixelOptics, Inc.
|
Dec. 31, 2012
PixelOptics, Inc.
|
Aug. 31, 2012
MediaMath, Inc.
|
Dec. 31, 2012
MediaMath, Inc.
|
Feb. 29, 2012
Spongecell
|
Dec. 31, 2011
Hoopla Software, Inc.
|
Nov. 30, 2011
Medivo, Inc.
|
Sep. 30, 2011
Putney, Inc.
|
Aug. 31, 2011
Swap.com
|
Jun. 30, 2011
NovaSom, Inc.
|
Apr. 30, 2009
Portico
|
Dec. 31, 2010
Portico
|
Dec. 31, 2010
AdvantEdge Healthcare Solutions, Inc.
|
Dec. 31, 2009
AdvantEdge Healthcare Solutions, Inc.
|
Mar. 31, 2010
AdvantEdge Healthcare Solutions, Inc.
|
Sep. 30, 2010
Clarient
|
Nov. 30, 2012
DriveFactor Inc.
|
Dec. 31, 2011
DriveFactor Inc.
|
Oct. 31, 2012
Good Start Genetics, Inc.
|
Dec. 31, 2010
Good Start Genetics, Inc.
|
Oct. 31, 2012
NuPathe
|
Aug. 31, 2010
NuPathe
|
Apr. 30, 2010
NuPathe
|
Aug. 31, 2009
NuPathe
|
Aug. 31, 2012
Penn Mezzanine
|
Jan. 31, 2012
Penn Mezzanine
|
Aug. 31, 2011
Penn Mezzanine
|
Dec. 31, 2012
Penn Mezzanine
|
Dec. 31, 2011
Penn Mezzanine
|
Dec. 31, 2012
Penn Mezzanine
Maximum
|
Jul. 31, 2012
Alverix, Inc.
|
Oct. 31, 2011
Alverix, Inc.
|
Feb. 29, 2012
Lumesis
|
Oct. 31, 2009
Quinnova Pharmaceuticals
|
Sep. 30, 2010
Quinnova Pharmaceuticals
|
Apr. 30, 2010
Tengion
|
Dec. 31, 2008
Tengion
|
Dec. 31, 2012
Crescendo Bioscience, Inc.
|
Dec. 31, 2012
Appfirst
|
|
Schedule of Equity Method Investments [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Ownership interest under the equity method, percentage | 23.10% | 28.00% | 30.00% | 30.10% | 31.70% | 36.00% | 31.60% | 12.60% | 35.00% | ||||||||||||||||||||||||||||||||||||
Acquisitions of ownership interests in companies and funds, net of cash acquired | $ 46,100,000 | $ 85,329,000 | $ 20,418,000 | $ 5,000,000 | $ 5,000,000 | $ 25,000,000 | $ 16,900,000 | $ 10,000,000 | $ 1,300,000 | $ 6,300,000 | $ 10,000,000 | $ 8,100,000 | $ 20,000,000 | $ 9,300,000 | $ 1,800,000 | $ 13,500,000 | $ 1,800,000 | $ 1,700,000 | $ 5,200,000 | $ 6,800,000 | $ 3,900,000 | $ 13,900,000 | $ 26,100,000 | $ 7,600,000 | $ 2,200,000 | $ 5,000,000 | $ 10,000,000 | $ 6,500,000 | |||||||||||||||||
Acquisitions of ownership interests in companies as available-for-sale securities | 5,000,000 | 3,500,000 | 12,000,000 | 1,500,000 | 7,500,000 | ||||||||||||||||||||||||||||||||||||||||
Number of preferred stock units and warrants purchased | 2,500 | ||||||||||||||||||||||||||||||||||||||||||||
Convertible bridge loan | 6,600,000 | 2,400,000 | 2,700,000 | 1,200,000 | 700,000 | ||||||||||||||||||||||||||||||||||||||||
Shares of common stock to be purchased with preferred stock units and warrants | 2,500,000 | ||||||||||||||||||||||||||||||||||||||||||||
Company fund amount for convertible debt | 1,700,000 | ||||||||||||||||||||||||||||||||||||||||||||
Fund amount for participations in loan and equity interests | 1,700,000 | 2,500,000 | 9,700,000 | ||||||||||||||||||||||||||||||||||||||||||
Fund amount for participations in loan | 1,500,000 | 2,300,000 | 8,100,000 | ||||||||||||||||||||||||||||||||||||||||||
Fund amount for participations in equity interests | 100,000 | 200,000 | 1,300,000 | ||||||||||||||||||||||||||||||||||||||||||
Fund amount for participations in warrants | 100,000 | 300,000 | |||||||||||||||||||||||||||||||||||||||||||
Company funded for early and growth stage | 400,000 | ||||||||||||||||||||||||||||||||||||||||||||
Percentage of limited partnership interest | 9.40% | ||||||||||||||||||||||||||||||||||||||||||||
Mezzanine debt financing | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||
Company fund amount for short-term loan | 1,300,000 | ||||||||||||||||||||||||||||||||||||||||||||
Warrants exercised, value | $ 600,000 |